circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1.

Cheng Z, Yu C, Cui S, Wang H, Jin H, Wang C, Li B, Qin M, Yang C, He J, Zuo Q, Wang S, Liu J, Ye W, Lv Y, Zhao F, Yao M, Jiang L, Qin W. · 2019

Read circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. by Cheng Z, Yu C, Cui S, Wang H, Jin H, Wang C, Li B, Qin M, Yang C, He J, Zuo Q, Wang S, Liu J, Ye W, Lv Y, Zhao F, Yao M, Jiang L, Qin W. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6642174.txt.

Introduction

Cheng and co-authors identify a circular RNA that promotes lung squamous cell carcinoma. Their study appears in Nature Communications. Roles for circular RNAs in this cancer type were largely unknown. The team profiled RNA in five paired tumour samples. One cell-cycle-linked loop, circTP63, stood out as raised. High levels tracked larger tumours and higher stage. Experiments showed the loop speeds cell growth. It did so in culture and in animals.

The mechanism works through microRNA sponging. circTP63 binds miR-873-3p and keeps it from its target. That target, FOXM1, then rises in level. FOXM1 lifts CENPA and CENPB in turn. Together they push the cell cycle forward. The authors nominate circTP63 for diagnosis and therapy.

Catalog record

CREATORCheng Z, Yu C, Cui S, Wang H, Jin H, Wang C, Li B, Qin M, Yang C, He J, Zuo Q, Wang S, Liu J, Ye W, Lv Y, Zhao F, Yao M, Jiang L, Qin W.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6642174

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1 By Zhuoan Cheng, Chengtao Yu, Shaohua Cui, Hui Wang, Haojie Jin, Cun Wang, Botai Li, Meilin Qin, Chen Yang, Jia He, Qiaozhu Zuo, Siying Wang Published in: Nature Communications DOI: 10.1038/s41467-019-11162-4 ABSTRACT Abstract Circular RNAs (circRNAs) are identified as vital regulators in a variety of cancers. However, the role of circRNA in lung squamous cell carcinoma (LUSC) remains largely unknown. Herein, we explore the expression profiles of circRNA and mRNA in 5 paired samples of LUSC. By analyzing the co-expression network of differentially expressed circRNAs and dysregulated mRNAs, we identify that a cell cycle-related circRNA, circTP63, is upregulated in LUSC tissues and its upregulation is correlated with larger tumor size and higher TNM stage in LUSC patients. Elevated circTP63 promotes cell proliferation both in vitro and in vivo. Mechanistically, circTP63 shares miRNA response elements with FOXM1. circTP63 competitively binds to miR-873-3p and prevents miR-873-3p to decrease the level of FOXM1, which upregulates CENPA and CENPB, and finally facilitates cell cycle progression. Subject terms: Non-small-cell lung cancer, Non-small-cell lung cancer INTRODUCTION Lung cancer is the most common incident cancer and the leading cause of cancer death worldwide1. In China, there were ~0.73 million newly diagnosed and 0.61 million death due to lung cancer in 20152. Overall, 80–85% of all human lung cancers are non-small cell lung cancer (NSCLC), of which lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) are the major subtypes. Recently, the development of targeted drugs for specific gene mutations has greatly improved the therapy of advanced LUAD patients. In contrast, only a small proportion of LUSC harbor driver gene mutations, leading to a 5-year survival rate <5% due to compromised efficacy of platinum-based chemotherapy for LUSC3. Therefore, it is critical to further address the molecular mechanisms underlying the development and progression of LUSC for the development of more effective treatment options. Lung cancer results from multiple complex combinations of morphological, molecular, and genetic alterations4. Noncoding RNAs are transcribed from a large proportion of human genome and regulate gene expression5. Recently, circular RNAs (circRNAs) as a type of regulatory RNAs have attracted great research interest. circRNAs are characterized by covalently closed loop structures with neither 5′–3′ polarity nor a polyadenylated tail6. They are abundant, conserved stable and tissue or developmental-stage specific7,8. With accumulated knowledge of characteristics and functions of circRNAs, it has been described that circRNAs play important roles in human diseases, such as atherosclerotic vascular disease9, neurological disorders10, heart disease11, and cancer12–14. To date, circRNAs functioning as the competing endogenous RNA (ceRNA) have been most widely reported in various types of cancer. For example, multiple cancer-related CDR1as15–18, hepatocellular carcinoma suppressor cSMARCA519 and circMTO120, and oncogenic circCCDC66 in colon cancer progression21, act as miRNA sponges to involve in cancer development. Besides the ceRNA mechanism, circRNAs can interact with RNA-binding proteins to regulate gene expressions22and some of them can encode functional proteins23,24. Moreover, circRNAs have potential to be biomarkers for disease diagnosis25,26. In lung cancer, a group of circRNAs have been found to be significantly dysregulated27,28 and several LUAD-related circRNAs are identified. For example, circPRKCI and Fusion-circEA1 (generated by the EMF4/ALK1 fusion gene) may act as oncogenic circRNAs29,30. circRNA-ITCH may serve as a tumor suppressor by upregulating ITCH expression31. Although circRNAs has been identified to be crucial for LUAD progression, the roles of circRNAs in LUSC are largely unknown. Xu and colleagues briefly investigate the expression profile of circRNAs in three LUSC and matched nontumorous tissues by an array analysis only containing probes for circRNA32. However, roles and mechanisms of circRNAs in LUSC have not been explored comprehensively. In this study, we investigate the expression profiling of circRNA and mRNA in five LUSC and paired adjacent tissues through a microarray containing probes for circRNAs and mRNAs. Then, a significant upregulated circRNA, hsa_circ_0068515, designated as circTP63, is initially identified. circTP63 is correlated with larger tumor size and higher TNM stage in LUSC patients and promotes cell proliferation by functioning as a ceRNA to upregulate FOXM1. Our results indicate that circTP63 exerts oncogenic potential and it may be a candidate in diagnosis and treatment of LUSC. RESULTS circTP63 is upregulated in LUSC We simultaneously analyzed the expression profiles of circRNA and mRNA in five paired samples of LUSC and matched nontumorous tissues by SBC Human ceRNA Array, which contains 88,371 circRNA probes, 77,103 lncRNA probes, and 18,853 mRNA probes (GEO Submisstion: GSE126533) (www.ncbi.nlm.nih.gov/geo). A total of 7081 dysregulated circRNAs were identified in LUSC tissues, of which 3157 circRNAs were upregulated and 3924 circRNAs were downregulated (step 1 in Fig. 1a and Supplementary Fig. 1a, b). In addition, 2832 differentially expressed mRNAs were also identified, with 979 mRNAs upregulated and 1853 mRNAs downregulated (step 1 in Fig. 1a and Supplementary Fig. 1c, d). To explore crucial circRNAs that involved in LUSC, we did co-expression network analysis between the top 100 mostly changed circRNAs (step 2 in Fig. 1a, b and Supplementary Table 1) and 109 dysregulated genes in cell cycle which was the main pathway revealed by KEGG pathway analysis (Fig. 1c). The network implied that 6 circRNAs and 79 mRNAs might involve in cell cycle regulation (step 3 in Fig. 1a and Supplementary Fig. 2a). To check the resistance of the six circRNAs to RNase R digestion, circRNA candidates were analyzed by reverse transcription PCR (RT-PCR) after RNase R treatment. The levels of linear isoform were used to illustrate the efficacy of RNase R treatment. Results showed that only hsa_circ_0068515 (termed circTP63) was more resistant to RNase R treatment compared to TP63 linear isoform (step 4 in Fig. 1a and d). hsa_circ_0026398 and hsa_circ_0074026 could not be detected due to their very low abundance in lung cancer cells. For hsa_circ_0026443, we tried different primers to amplify this circRNA, but all of these primers caused nonspecific amplification. hsa_circ_0026414 and hsa_circ_0019089 were sensitive to RNase R, suggesting that some identified circRNAs may be false positives. In addition, we selected other 10 circRNAs (five upregulated and five downregulated circRNAs) from the top 20 dysregulated circRNAs to verify the microarray results. Sanger sequencing confirmed their back-spiced junctions (Supplementary Fig. 1e). qRT-PCR analysis showed that the expression of these 10 circRNAs was consistent with the result of microarray (Supplementary Fig. 1f). [Figure: circRNA expression profiling reveals that circTP63 is upregulated in LUSC. a The flowchart delineates the steps for identifying and validating circRNAs in LUSC. b A heatmap shows the top 50 most upregulated and top 50 most downregulated circRNAs in five paired samples of tumorous tissues (T) and corresponding adjacent nontumorous tissues (N) from patients with LUSC by SBC Human ceRNA Array analysis. c KEGG pathway analysis for the 2832 dysregulated mRNAs. d Validation of six circRNAs by RNase R treatment and reverse transcription PCR (RT-PCR) analysis. e Fold change of circTP63 in the five paired samples of LUSC for SBC Human ceRNA Array analysis. f Left: expression levels of circTP63 in additional 35 paired samples of LUSC were determined by quantitative reverse transcription PCR (qRT-PCR). β-actin was used as a loading control. Right: histogram and pie chart of the proportions of LUSC samples in which circTP63 expression was upregulated (23/35, 65.7%, red), downregulated (7/35, 20%, blue), or no change

Read the complete text